ASCEND-2: A single-arm, open-label, multicenter phase II study of ceritinib in adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ).

Tony S.K. Mok, David Robert Spigel, Enriqueta Felip et al. · Journal of Clinical Oncology · 2015

8059 Background: In the ASCEND-1 study ceritinib showed clinical activity in pts with ALK+ NSCLC, including in brain metastases (BM). ASCEND-2 (NCT01685060) evaluated efficacy and safety of ceritinib in ALK+ NSCLC pts pre-treated with chemotherapy (≥ 1 platinum doublet) who progressed ≤30 days from last treatment with CRZ. Methods: At August 2014 data cut-off, 140 pts receiving oral ceritinib 750 mg daily had enrolled worldwide. Whole body (WB) and intracranial (I) responses were assessed by investigator; Lung Cancer Symptom Scale (LCSS) and EORTC (QLQ-C30) surveys assessed patient reported outcomes. Results: Of 140 pts: median age (range) 51 (29–80) years; 50.0% male; 60.0% Caucasian; 37.9% Asian; 71.4% with BM, of which 28.0% had no prior brain radiation (BRT). Median duration of exposure and follow-up time were 8.8 (0.1–19.4) and 11.3 (0.1–18.9) mos, respectively. At baseline, 20 pts had investigator-assessed measurable brain lesions (MBL); IDCR was 80.0% (95% CI: 56.3, 94.3); in 5 of 6 pts with MBL and no prior brain radiation, brain responses (2 CR, 3 PR) matched or exceeded WB response. Most common AEs (mostly Grade 1/2) were nausea (81.4%), diarrhea (80.0%), vomiting (62.9%). Eleven (7.9%) pts discontinued due to AEs, with no one AE predominating. LCSS showed improvement in symptom burden (-1.4 to -6.2). Global quality of life score (QLQ-C30) was maintained on treatment, with no substantial change from baseline (-1.5 to +4.6). Conclusions: Ceritinib provided durable responses and safety outcomes in CRZ-pretreated patients with or without BM consistent with those seen in ASCEND-1. Clinical trial information: NCT01685060.Investigator-assessed efficacy outcomes. BM N=100 No BM N=40 All N=140 WB ORR (CR+PR), n (%) [95% CI] 33 (33.0) [23.9, 43.1] 21 (52.5) [36.1, 68.5] 54 (38.6) [30.5, 47.2] WB DCR (CR+PR+SD), n (%) [95% CI] 74 (74.0) [64.3, 82.3] 34 (85.0) [70.2, 94.3] 108 (77.1) [69.3, 83.8] Median Duration of Response, Mos [95% CI] 9.2 [5.5, 11.1] 10.3 [7.4, 16.6] 9.7 [7.1, 11.1] Median Progression Free Survival (PFS) Mos [95% CI] 5.4 [4.7,7.2] 11.3 [5.7,15.6] 5.7 [5.4, 7.6]

Cited by 76 works. doi:10.1200/jco.2015.33.15_suppl.8059

Authors